Dabrafenib protects from cisplatin-induced hearing loss in a clinically relevant mouse model

The widely used chemotherapy cisplatin causes permanent hearing loss in 40%–60% of patients with cancer. One drug, sodium thiosulfate, is approved by the FDA for use in pediatric patients with localized solid tumors for preventing cisplatin-induced hearing loss, but more drugs are desperately needed...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Matthew A. Ingersoll, Richard D. Lutze, Chithra K. Pushpan, Regina G. Kelmann, Huizhan Liu, Mark T. May, William J. Hunter, David Z.Z. He, Tal Teitz
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	American Society for Clinical investigation 2023-12-01
Saila:	JCI Insight
Gaiak:	Otology Therapeutics
Sarrera elektronikoa:	https://doi.org/10.1172/jci.insight.171140
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!